Industry vets Damien
Fischer and Tim Germann bring
decades of market experience in the life sciences and analytical
tools
CHARLOTTESVILLE, Va. and WALTHAM, Mass., July 11,
2024 /PRNewswire/ -- BrightSpec, the market leader in
Molecular Rotational Resonance (MRR) spectroscopy solutions,
announced today the appointment of two new executives to drive the
commercialization of their growing portfolio of precision
instruments and analytical tools.
BrightSpec develops and commercializes instruments that harness
the power of MRR spectroscopy, an innovative approach to rapidly
and definitively characterize the unique three-dimensional
structure of small molecules for pharmaceutical, industrial, and
research customers. BrightSpec is developing a vertically
integrated platform with predictive software, automated
instrumentation, and data analysis tools.
With today's announcement, Damien
Fischer, most recently the Senior Vice President of Global
Sales and Support at Syft Technologies, joins BrightSpec to lead
its customer-facing functions as Global VP of Sales and Service. At
Syft, Mr. Fischer grew revenue more than 20-fold during his
four-year tenure and built a global sales, applications, and
support infrastructure for Syft's unique mass spectrometry product
line. Prior to Syft, Mr. Fischer spent 15 years at Agilent
Technologies in senior sales and business development roles.
"Adding a commercial operating executive like Damien will help
make BrightSpec a force in the molecular characterization market,"
says Walter Colsman, Chief Executive
of BrightSpec. "Damien immediately enhances a budding commercial
presence and will take us to a new level of market penetration and
customer awareness."
Tim Germann joins BrightSpec's
Board of Directors as an Independent Director focused on helping
the management team establish compelling value propositions,
penetrate the life science, chemical, and consumer goods
industries, and build enterprise value. Mr. Germann currently
serves as Chief Commercial Officer of Carterra, the leading
provider of label-free biosensing technology for drug discovery.
Mr. Germann has spent 34 years becoming an expert in early-stage
commercialization at Affymetrix (now Thermo
Fisher), Molecular Devices (now Danaher), and Metabolon. He
is a published author, lecturer, and advisor to various life
science start-ups.
"BrightSpec's leadership team continues to demonstrate their
ability to bring in top talent to help drive their next phase of
growth," said Jenny Rooke, Ph.D.,
Founder and Managing Director at Genoa Ventures. "Having known
Tim Germann for 25 years, I am
thrilled to have him join the Board of Directors, as his expertise
will provide vital strategic guidance as BrightSpec accelerates
commercialization."
About BrightSpec
BrightSpec, Inc. is the leading provider of Molecular Rotational
Resonance (MRR) spectrometry solutions. Combining the structural
power of NMR with the speed, accuracy, and precision of Mass
Spectrometry, MRR provides comprehensive small molecule
identification in a single instrument. Rapid, accurate results are
obtained directly from complex samples by eliminating the need for
chromatography. To date, BrightSpec has empowered customers with
proven solutions across the pharmaceutical, consumer, and
industrial chemical industries.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/brightspec-adds-commercial-firepower-to-its-leadership-team-and-board-of-directors-302193900.html
SOURCE BrightSpec